valproic acid has been researched along with Amentia in 51 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Valproic acid should not or carefully be used as it can affect the risk of developing dementia." | 9.41 | [Effects of lithium, valproic acid, carbamazepine and antipsychotic agents on cognition in bipolar disorders-A systematic review]. ( Leopold, S; Quante, A, 2023) |
| "Valproic acid is widely used in the treatment of behavioral disturbances in patients with dementia; however, there is uncertainty about its dosing and studies have reported mixed findings." | 8.88 | Valproic acid in dementia: does an optimal dose exist? ( Dolder, CR; McKinsey, J; Nealy, KL, 2012) |
| "To determine whether evidence supports the use of valproic acid in the treatment of agitation of people with dementia." | 8.82 | Valproic acid for agitation in dementia. ( Cameron, M; Lonergan, ET; Luxenberg, J, 2004) |
| "Although valproate and lithium are most commonly prescribed for bipolar disorder patients, studies comparing their effects on the risk of dementia are limited." | 8.12 | Effect of valproate and lithium on dementia onset risk in bipolar disorder patients. ( Ji, E; Kim, KW; Kwon, JS; Moon, W; Shin, J, 2022) |
| "Valproic acid (VPA) is widely used for treating patients with bipolar disorder; however, it has adverse effects on cognitive function." | 7.83 | Effect of valproic acid on dementia onset in patients with bipolar disorder. ( Chiu, CH; Huang, CJ; Liu, IC; Tsai, PS; Wang, MY, 2016) |
| "Valproic acid (VPA) is associated with hyperammonemia; however, little is known about this phenomenon in the geriatric psychiatric population." | 7.78 | Hyperammonemia associated with valproic acid use in elderly psychiatric patients. ( Holroyd, S; Overdyke, JT, 2012) |
| "In addition to the usual adverse effects, the chronic use of the valproic acid can entail dementia syndrome." | 7.74 | [Dementia syndrome in an elderly subject related to valproic acid use: a case report]. ( Disson-Dautriche, A; Manckoundia, P; Pfitzenmeyer, P; Richard, D; Rouaud, O; Tavernier-Vidal, B, 2008) |
| "Valproic acid, an anticonvulsant medication that enhances GABAergic neurotransmission, has been shown to be helpful in treating behavioural disturbances associated with dementia in several small case series." | 7.70 | Valproic acid treatment of agitation in dementia. ( Herrmann, N, 1998) |
| "Results: Mild cognitive impairment - MCI was diagnosed in 4 patients (28." | 5.72 | HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY. ( Dutkiewicz, J; Pilut, D; Szczygieł-Pilut, EE; Zajączkowska-Dutkiewicz, A, 2022) |
| " Valproic acid should not or carefully be used as it can affect the risk of developing dementia." | 5.41 | [Effects of lithium, valproic acid, carbamazepine and antipsychotic agents on cognition in bipolar disorders-A systematic review]. ( Leopold, S; Quante, A, 2023) |
| "Valproic acid (VPA) has been reported to cause cognitive decline and parkinsonism that are reversed with cessation of medication." | 5.37 | Reversible dementia and gait disturbance after prolonged use of valproic acid. ( Evans, MD; Shinar, R; Yaari, R, 2011) |
| "Valproic acid is widely used in the treatment of behavioral disturbances in patients with dementia; however, there is uncertainty about its dosing and studies have reported mixed findings." | 4.88 | Valproic acid in dementia: does an optimal dose exist? ( Dolder, CR; McKinsey, J; Nealy, KL, 2012) |
| " The purpose of this review of the literature is to assess the interest and the limits of anticonvulsant mood stabilizers (carbamazepine, valproic acid, gabapentin, lamotrigine, topiramate, oxcarbazepine) in the treatment of the so-called "noncognitive" symptoms of dementia." | 4.84 | [Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)]. ( Pinheiro, D, 2008) |
| "To review and summarize the currently available data on the use of anticonvulsant mood stabilizers (carbamazepine, valproic acid, gabapentin, lamotrigine, topiramate) in the treatment of behavioral and psychological symptoms of dementia (BPSD); to determine whether these medications can be recommended for routine clinical use." | 4.84 | Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. ( Konovalov, S; Muralee, S; Tampi, RR, 2008) |
| "To determine whether evidence supports the use of valproic acid in the treatment of agitation of people with dementia." | 4.82 | Valproic acid for agitation in dementia. ( Cameron, M; Lonergan, ET; Luxenberg, J, 2004) |
| "Although valproate and lithium are most commonly prescribed for bipolar disorder patients, studies comparing their effects on the risk of dementia are limited." | 4.12 | Effect of valproate and lithium on dementia onset risk in bipolar disorder patients. ( Ji, E; Kim, KW; Kwon, JS; Moon, W; Shin, J, 2022) |
| "Valproic acid (VPA) is widely used for treating patients with bipolar disorder; however, it has adverse effects on cognitive function." | 3.83 | Effect of valproic acid on dementia onset in patients with bipolar disorder. ( Chiu, CH; Huang, CJ; Liu, IC; Tsai, PS; Wang, MY, 2016) |
| " Department of Veterans Affairs (fiscal years 1999-2008) for dementia patients age 65 and older who began outpatient treatment with an antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) or valproic acid and its derivatives (as a nonantipsychotic comparison)." | 3.78 | Risk of mortality among individual antipsychotics in patients with dementia. ( Blow, FC; Chiang, C; Cunningham, F; Kales, HC; Kim, HM; Schneider, LS; Seyfried, LS; Valenstein, M; Zivin, K, 2012) |
| "Valproic acid (VPA) is associated with hyperammonemia; however, little is known about this phenomenon in the geriatric psychiatric population." | 3.78 | Hyperammonemia associated with valproic acid use in elderly psychiatric patients. ( Holroyd, S; Overdyke, JT, 2012) |
| "In addition to the usual adverse effects, the chronic use of the valproic acid can entail dementia syndrome." | 3.74 | [Dementia syndrome in an elderly subject related to valproic acid use: a case report]. ( Disson-Dautriche, A; Manckoundia, P; Pfitzenmeyer, P; Richard, D; Rouaud, O; Tavernier-Vidal, B, 2008) |
| "Valproic acid, an anticonvulsant medication that enhances GABAergic neurotransmission, has been shown to be helpful in treating behavioural disturbances associated with dementia in several small case series." | 3.70 | Valproic acid treatment of agitation in dementia. ( Herrmann, N, 1998) |
| "VPM maybe plays an active role in the treatment of dementia patients and this research will provide reliable evidence for clinicians in therapy of PwD." | 3.01 | Magnesium valproate adjuvant therapy on patients with dementia: A protocol for systematic review and meta-analysis. ( Sun, H; Sun, LQ; Zhang, CQ; Zheng, KX, 2021) |
| "The phenytoin treatment causes cerebellar defect and anemia." | 2.82 | The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches. ( Agrawal, M; Dhurandhar, Y; Panda, SP, 2022) |
| "The goal of this study was to determine if manifestations of agitation (ie, physical aggression, physically nonaggressive behavior, and verbally agitated behaviors) show different degrees of response to divalproex sodium (extended release or sprinkles) alone or in combination with second-generation antipsychotic agents." | 2.73 | Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication. ( Adkison, L; Ahokpossi, C; Forester, B; Hyde, J; Perez, R; Sribney, W; Vanelli, M, 2007) |
| "Valproic acid derivatives have been used for the past 10 years to control agitation in dementia, but no systematic review of the effectiveness of this treatment has been published to date." | 2.45 | Valproate preparations for agitation in dementia. ( Lonergan, E; Luxenberg, J, 2009) |
| "Results: Mild cognitive impairment - MCI was diagnosed in 4 patients (28." | 1.72 | HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY. ( Dutkiewicz, J; Pilut, D; Szczygieł-Pilut, EE; Zajączkowska-Dutkiewicz, A, 2022) |
| "We describe arginase deficiency in a 20-year-old woman with spastic paraplegia, progressive dystonia, dementia, peripheral neuropathy, epilepsy, liver cirrhosis, and non-B/non-C hepatocellular carcinoma." | 1.38 | Arginase deficiency with new phenotype and a novel mutation: contemporary summary. ( Ching, CK; Fung, CW; Lam, CW; Luk, HM; Mak, CM; Poon, WL; Siu, TS; Tam, S; Tsang, JP; Wong, VC, 2012) |
| "Cyproterone acetate was used in a small number of patients at each of the three units." | 1.37 | Pharmacological treatment of behavioural and psychological symptoms of dementia in psychogeriatric inpatient units. ( Lemon, V; Restifo, S; Waters, F, 2011) |
| "Valproic acid (VPA) has been reported to cause cognitive decline and parkinsonism that are reversed with cessation of medication." | 1.37 | Reversible dementia and gait disturbance after prolonged use of valproic acid. ( Evans, MD; Shinar, R; Yaari, R, 2011) |
| "We diagnosed this case as Lissauer's general paresis and treated with intravenous benzylpenicillin potassium 24 million units per day for 2 weeks." | 1.36 | [A case of Lissauer form of paretic neurosyphilis with drop attacks and dementia]. ( Arahata, S; Araki, E; Fujii, N; Furuya, H; Syouzaki, T, 2010) |
| " The patient's regular physicians managed all treatment decisions, including decisions on dosage and plasma level measurements of sodium valproate and decisions regarding discontinuation." | 1.32 | Sodium valproate in aggressive behaviour in dementia: a twelve-week open label follow-up study. ( Duivenvoorden, HJ; Duursma, SA; Eikelenboom, P; Haffmans, PM; Jansen, PA; Sival, RC, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.92) | 18.7374 |
| 1990's | 10 (19.61) | 18.2507 |
| 2000's | 18 (35.29) | 29.6817 |
| 2010's | 15 (29.41) | 24.3611 |
| 2020's | 6 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, CQ | 1 |
| Zheng, KX | 1 |
| Sun, LQ | 1 |
| Sun, H | 1 |
| Panda, SP | 1 |
| Dhurandhar, Y | 1 |
| Agrawal, M | 1 |
| Szczygieł-Pilut, EE | 1 |
| Zajączkowska-Dutkiewicz, A | 1 |
| Pilut, D | 1 |
| Dutkiewicz, J | 1 |
| Moon, W | 1 |
| Ji, E | 1 |
| Shin, J | 1 |
| Kwon, JS | 1 |
| Kim, KW | 1 |
| Leopold, S | 1 |
| Quante, A | 1 |
| Lindley, RI | 1 |
| Baillon, SF | 1 |
| Narayana, U | 1 |
| Luxenberg, JS | 1 |
| Clifton, AV | 1 |
| Tsai, PS | 1 |
| Liu, IC | 1 |
| Chiu, CH | 1 |
| Huang, CJ | 1 |
| Wang, MY | 1 |
| Shao, SC | 1 |
| Wu, WH | 1 |
| Yang, YK | 1 |
| Lai, EC | 1 |
| Manckoundia, P | 1 |
| Disson-Dautriche, A | 1 |
| Rouaud, O | 1 |
| Richard, D | 1 |
| Tavernier-Vidal, B | 1 |
| Pfitzenmeyer, P | 1 |
| Pinheiro, D | 1 |
| Penot, JP | 1 |
| Pradeau, F | 1 |
| Lonergan, E | 1 |
| Luxenberg, J | 2 |
| Gareri, P | 1 |
| Lacava, R | 1 |
| Cotroneo, A | 1 |
| Bambara, V | 1 |
| Marigliano, N | 1 |
| Castagna, A | 1 |
| Costantino, DS | 1 |
| Ruotolo, G | 1 |
| de Sarro, G | 1 |
| Sleegers, MJ | 1 |
| Beutler, JJ | 1 |
| Hardon, WJ | 1 |
| Berden, JH | 1 |
| Verhave, JC | 1 |
| Conemans, JM | 1 |
| Hollander, DA | 1 |
| Dautzenberg, PL | 1 |
| Hoogeveen, EK | 1 |
| Syouzaki, T | 1 |
| Arahata, S | 1 |
| Araki, E | 1 |
| Furuya, H | 1 |
| Fujii, N | 1 |
| Mizukami, K | 1 |
| Hatanaka, K | 1 |
| Ishii, T | 1 |
| Iwakiri, M | 1 |
| Sodeyama, N | 1 |
| Tanaka, Y | 1 |
| Asada, T | 1 |
| Restifo, S | 1 |
| Lemon, V | 1 |
| Waters, F | 1 |
| Evans, MD | 1 |
| Shinar, R | 1 |
| Yaari, R | 1 |
| Dolder, CR | 1 |
| Nealy, KL | 1 |
| McKinsey, J | 1 |
| Kales, HC | 1 |
| Kim, HM | 1 |
| Zivin, K | 1 |
| Valenstein, M | 1 |
| Seyfried, LS | 1 |
| Chiang, C | 1 |
| Cunningham, F | 1 |
| Schneider, LS | 1 |
| Blow, FC | 1 |
| Yeh, YC | 1 |
| Ouyang, WC | 1 |
| Roehr, B | 1 |
| Tsang, JP | 1 |
| Poon, WL | 1 |
| Luk, HM | 1 |
| Fung, CW | 1 |
| Ching, CK | 1 |
| Mak, CM | 1 |
| Lam, CW | 1 |
| Siu, TS | 1 |
| Tam, S | 1 |
| Wong, VC | 1 |
| Holroyd, S | 1 |
| Overdyke, JT | 1 |
| Sival, RC | 3 |
| Haffmans, PM | 3 |
| Jansen, PA | 2 |
| Duursma, SA | 2 |
| Eikelenboom, P | 2 |
| Pratt, CE | 1 |
| Davis, SM | 1 |
| Shulman, KI | 1 |
| Rochon, P | 1 |
| Sykora, K | 1 |
| Anderson, G | 1 |
| Mamdani, M | 1 |
| Bronskill, S | 1 |
| Tran, CT | 1 |
| Duivenvoorden, HJ | 1 |
| Lonergan, ET | 1 |
| Cameron, M | 1 |
| Green, B | 1 |
| Meinhold, JM | 1 |
| Blake, LM | 1 |
| Mini, LJ | 1 |
| Welge, JA | 1 |
| Schwiers, M | 1 |
| Hughes, A | 1 |
| Porsteinsson, AP | 2 |
| Hollis, J | 1 |
| Grayson, D | 1 |
| Forrester, L | 1 |
| Brodaty, H | 1 |
| Touyz, S | 1 |
| Cumming, R | 1 |
| Forester, B | 1 |
| Vanelli, M | 1 |
| Hyde, J | 1 |
| Perez, R | 1 |
| Ahokpossi, C | 1 |
| Sribney, W | 1 |
| Adkison, L | 1 |
| Gálvez-Andres, A | 1 |
| Blasco-Fontecilla, H | 1 |
| González-Parra, S | 1 |
| Molina, JD | 1 |
| Padín, JM | 1 |
| Rodriguez, RH | 1 |
| Konovalov, S | 1 |
| Muralee, S | 1 |
| Tampi, RR | 1 |
| Iivanainen, M | 1 |
| Bergström, L | 1 |
| Nuutila, A | 1 |
| Viukari, M | 1 |
| Papazian, O | 1 |
| Cañizales, E | 1 |
| Alfonso, I | 1 |
| Archila, R | 1 |
| Duchowny, M | 1 |
| Aicardi, J | 1 |
| Lott, AD | 1 |
| McElroy, SL | 1 |
| Keys, MA | 1 |
| Puryear, LJ | 1 |
| Kunik, ME | 2 |
| Molinari, V | 2 |
| Workman, RH | 2 |
| van Gent, PP | 1 |
| van Nieuwkerk, JF | 1 |
| Walstra, GJ | 1 |
| Haas, S | 1 |
| Vincent, K | 1 |
| Holt, J | 1 |
| Lippmann, S | 1 |
| Puryear, L | 1 |
| Orengo, CA | 1 |
| Herrmann, N | 1 |
| Narayan, M | 1 |
| Nelson, JC | 1 |
| Raskind, MA | 1 |
| Tariot, PN | 1 |
| Erb, R | 1 |
| Cox, C | 1 |
| Smith, E | 1 |
| Jakimovich, L | 1 |
| Noviasky, J | 1 |
| Kowalski, N | 1 |
| Holt, CJ | 1 |
| Irvine, C | 1 |
| Rhodes-Kropf, J | 1 |
| Lantz, MS | 1 |
| Mirsky, AF | 1 |
| Duncan, CC | 1 |
| Myslobodsky, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feru-guard (Ferulic Acid and Angelica Archangelica Extract) for Behavioral Symptoms in Dementia[NCT03451760] | Phase 2 | 70 participants (Anticipated) | Interventional | 2018-09-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for valproic acid and Amentia
| Article | Year |
|---|---|
The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches.
Topics: Anticonvulsants; Carbamazepine; Dementia; Epilepsy; Felbamate; Gabapentin; Humans; Inflammasomes; La | 2022 |
[Effects of lithium, valproic acid, carbamazepine and antipsychotic agents on cognition in bipolar disorders-A systematic review].
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamazepine; Cognition; | 2023 |
Valproate preparations for agitation in dementia.
Topics: Aged; Aggression; Antimanic Agents; Cognition; Dementia; Humans; Psychomotor Agitation; Randomized C | 2018 |
Quetiapine-induced absence seizures in a dementia patient.
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Dementia; Epilepsy, Absence; Female; Follow-Up Studies; | 2016 |
[Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)].
Topics: Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dementia; Fructose; Gabap | 2008 |
Valproate preparations for agitation in dementia.
Topics: Aged; Antimanic Agents; Dementia; Humans; Psychomotor Agitation; Randomized Controlled Trials as Top | 2009 |
Valproic acid in dementia: does an optimal dose exist?
Topics: Dementia; Dose-Response Relationship, Drug; Humans; Psychomotor Agitation; Psychotropic Drugs; Rando | 2012 |
Mood stabilizers for the treatment of behavioral and psychological symptoms of dementia: an update review.
Topics: Antipsychotic Agents; Carbamazepine; Dementia; Humans; Lamotrigine; Oxcarbazepine; Triazines; Valpro | 2012 |
Divalproex sodium therapy in elderly with dementia-related agitation.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Clinical Trials as Topic; Dementia; Humans; Psychomotor A | 2002 |
Valproic acid for agitation in dementia.
Topics: Aged; Antimanic Agents; Dementia; Humans; Psychomotor Agitation; Randomized Controlled Trials as Top | 2004 |
Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Dementia; Humans; Mental Disorders; Neuroprotecti | 2006 |
Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review.
Topics: Aggression; Amines; Anticonvulsants; Carbamazepine; Cognition Disorders; Cyclohexanecarboxylic Acids | 2008 |
Evaluation and management of aggressive behavior in the elderly demented patient.
Topics: Age Factors; Aged; Aggression; Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Cholinergic | 1999 |
Petit mal epilepsy: a review and integration of recent information.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Brain; Cognition; Dementia; Electroencephalogra | 1986 |
7 trials available for valproic acid and Amentia
| Article | Year |
|---|---|
Magnesium valproate adjuvant therapy on patients with dementia: A protocol for systematic review and meta-analysis.
Topics: Aged; Cognition; Dementia; Humans; Meta-Analysis as Topic; Systematic Reviews as Topic; Treatment Ou | 2021 |
Sodium valproate in the treatment of aggressive behavior in patients with dementia--a randomized placebo controlled clinical trial.
Topics: Aged; Aged, 80 and over; Aggression; Antimanic Agents; Cross-Over Studies; Dementia; Double-Blind Me | 2002 |
Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
Topics: Aged; Aged, 80 and over; Aggression; Antimanic Agents; Antipsychotic Agents; Behavioral Symptoms; De | 2007 |
Valproate in the treatment of behavioral agitation in elderly patients with dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Female; Humans; Male; Prospective Studies; | 1995 |
Divalproex: a possible treatment alternative for demented, elderly aggressive patients.
Topics: Aged; Aged, 80 and over; Aggression; Dementia; Female; GABA Agents; Geriatric Psychiatry; Humans; Lo | 1997 |
The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Drug Tolerance; Female; GABA Agents; Humans | 1998 |
Placebo-controlled study of divalproex sodium for agitation in dementia.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antimanic Agents; Dementia; Dose-Response Relationshi | 2001 |
30 other studies available for valproic acid and Amentia
| Article | Year |
|---|---|
HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY.
Topics: Ammonia; Anticonvulsants; Cognitive Dysfunction; Dementia; Epilepsy; Female; Humans; Hyperammonemia; | 2022 |
Effect of valproate and lithium on dementia onset risk in bipolar disorder patients.
Topics: Aged; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dementia; Humans; Lithium; Valproic | 2022 |
Do valproate preparations improve agitation in dementia? A Cochrane Review summary with commentary.
Topics: Anxiety; Dementia; Humans; Valproic Acid | 2021 |
Effect of valproic acid on dementia onset in patients with bipolar disorder.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Bipolar Disorder; Cohort Studies; Databases, Factua | 2016 |
[Dementia syndrome in an elderly subject related to valproic acid use: a case report].
Topics: Aged; Anticonvulsants; Dementia; Female; Humans; Valproic Acid | 2008 |
[Iatrogenic dementia and extrapyramidal syndrome: rare adverse effect of valproic acid-aspirin combination].
Topics: Aged; Anticonvulsants; Aspirin; Basal Ganglia Diseases; Dementia; Drug Interactions; Drug Therapy, C | 2010 |
Valproate-induced delirium in a demented patient.
Topics: Aged; Delirium; Dementia; Electroencephalography; Female; Follow-Up Studies; GABA Agents; Humans; Va | 2009 |
Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus.
Topics: Aged; Anticonvulsants; Dementia; Diagnosis, Differential; Disease Progression; Epilepsy, Generalized | 2010 |
[A case of Lissauer form of paretic neurosyphilis with drop attacks and dementia].
Topics: Dementia; Humans; Male; Middle Aged; Neurosyphilis; Syncope; Valproic Acid | 2010 |
Effects of sodium valproate on behavioral disturbances in elderly outpatients with dementia.
Topics: Aged; Aged, 80 and over; Aggression; Antimanic Agents; Dementia; Dose-Response Relationship, Drug; F | 2010 |
Pharmacological treatment of behavioural and psychological symptoms of dementia in psychogeriatric inpatient units.
Topics: Aged; Alzheimer Disease; Androgen Antagonists; Antipsychotic Agents; Cholinesterase Inhibitors; Cypr | 2011 |
Reversible dementia and gait disturbance after prolonged use of valproic acid.
Topics: Aged; Anticonvulsants; Cerebral Ventricles; Dementia; Female; Gait Disorders, Neurologic; Hearing Lo | 2011 |
Risk of mortality among individual antipsychotics in patients with dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dementia; Dibenzothiazepines; Female | 2012 |
Abbott pays $1.6bn for promoting off label use of valproic acid.
Topics: Aged; Dementia; Drug Industry; Humans; Off-Label Use; United States; Valproic Acid | 2012 |
Arginase deficiency with new phenotype and a novel mutation: contemporary summary.
Topics: Anticonvulsants; Arginase; Base Sequence; Carcinoma, Hepatocellular; Cerebral Palsy; Codon, Nonsense | 2012 |
Hyperammonemia associated with valproic acid use in elderly psychiatric patients.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Dementia; Female; Geriatrics; Humans; Hyperammonemia; Mal | 2012 |
Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Dementia; Humans; Lithium Carbonate; Practice Patterns, Ph | 2003 |
Sodium valproate in aggressive behaviour in dementia: a twelve-week open label follow-up study.
Topics: Aged; Aged, 80 and over; Aggression; Analysis of Variance; Antimanic Agents; Dementia; Drug Administ | 2004 |
Key developments in psychiatry.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cognitive Behavioral Therapy; Dementia; Hu | 2004 |
Effect of divalproex sodium on behavioural and cognitive problems in elderly dementia.
Topics: Aged; Aged, 80 and over; Anger; Antimanic Agents; Antipsychotic Agents; Behavioral Symptoms; Benzodi | 2005 |
Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older.
Topics: Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Antipsychotic Agents; Australia; Benzodiazepi | 2007 |
Secondary bipolar disorder and Diogenes syndrome in frontotemporal dementia: behavioral improvement with quetiapine and sodium valproate.
Topics: Antipsychotic Agents; Behavioral Symptoms; Bipolar Disorder; Dementia; Dibenzothiazepines; Female; H | 2007 |
Psychosis-like absence status of elderly patients: successful treatment with sodium valproate.
Topics: Dementia; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Therapy, Combination; Elec | 1984 |
Reversible dementia and apparent brain atrophy during valproate therapy.
Topics: Atrophy; Brain Diseases; Child; Child, Preschool; Dementia; Epilepsy; Female; Humans; Magnetic Reson | 1995 |
Psychiatric manifestations of temporal lobe epilepsy in older adults.
Topics: Aged; Dementia; Depressive Disorder; Diagnosis, Differential; Electroencephalography; Epilepsy, Temp | 1995 |
The effects of sodium valproate on disturbed behavior in dementia.
Topics: Aged; Aged, 80 and over; Behavior; Dementia; Female; Humans; Male; Valproic Acid | 1994 |
[Reversible dementia due to valproic acid therapy].
Topics: Aged; Anticonvulsants; Dementia; Epilepsy, Tonic-Clonic; Female; Frontal Lobe; Humans; Valproic Acid | 1997 |
Valproic acid treatment of agitation in dementia.
Topics: Aged; Aged, 80 and over; Dementia; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 1998 |
Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Drug Administration Sche | 1997 |
Alternative medicine. Achieving balance between herbal remedies and medical therapy.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Dementia; Drug Interactions; Female; Humans; Phytotherapy | 2001 |